Severe COVID-19 Infection in Children Presenting to EDs in Israel and England

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age0-16
SponsorHadassah Medical Organization

About this trial

Even though the COVID-19 pandemic is no longer at its peak, the threat still lingers. Engaging in prospective surveillance studies will enable us to monitor the disease and prepare for any potential resurgence. COVID-19 surveillance studies are essential tools for policymakers to make informed decisions, allocate resources, and develop strategies to control the spread of the virus and protect public health.

The objective of this surveillance study is to prospectively assess in-hospital severe morbidity related to COVID-19 infection in children who present to the Pediatric Emergency Department (ED).

A prospective multicenter study will be conducted across eight EDs in Israel and five EDs in the United Kingdom. The study population will include children aged 16 years or younger with a severe acute COVID-19 infection. Confirmation of acute COVID-19 infection will be based on polymerase chain reaction nasopharyngeal swab testing. The study will also include patients diagnosed with multisystem inflammatory syndrome in children (MIS-C), as defined by the CDC.

Eligibility criteria

Qualifiers

SACI

Receive oxygen via low-flow nasal cannula or oxygen mask, high-flow nasal cannula, bilevel or continuous positive airway pressure machine, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) Or

Admitted to ICU

MIS-C Patients aged 16 years or younger diagnosed with MIS-C

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Nasopharyngeal swab sampling for COVID-19

Treatment groups

500 Participants
are divided into 1 treatment group

Sponsors and collaborators

Hadassah Medical Organization

Lead sponsor

London North West Healthcare NHS Trust

Collaborator